Serveur d'exploration Tocilizumab - Merge (Accueil)

Index « Auteurs » - entrée « N. Miyasaka »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
N. Miyake < N. Miyasaka < N. Miyazaki  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
002D44 (2013) T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. MimoriOP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study)
002E81 (2013) Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon]FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy
003085 (2013) Y. Tanaka ; T. Abe ; T. Takeuchi ; A. Yamamoto ; N. Miyasaka [Japon]AB0587 Safety and efficacy of abatacept(ABA) demonstrated in patients with rheumatoid arthritis(RA); 4-year data from phase III open-label, multicenter, long-term extension trial
003257 (2013) Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort
004022 (2009) N. Nishimoto [Japon] ; N. Miyasaka [Japon] ; K. Yamamoto [Japon] ; S. Kawai [Japon] ; T. Takeuchi [Japon] ; J. Azuma [Japon]Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
004119 (2009) N. Nishimoto [Japon] ; N. Miyasaka [Japon] ; K. Yamamoto [Japon] ; S. Kawai [Japon] ; T. Takeuchi [Japon] ; J. Azuma [Japon]Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
004327 (2006) J. Ogawa [Japon] ; M. Harigai [Japon] ; T. Akashi [Japon] ; K. Nagasaka [Japon] ; F. Suzuki [Japon] ; S. Tominaga [Japon] ; N. Miyasaka [Japon]Exacerbation of chronic active Epstein–Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Merge
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "N. Miyasaka" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "N. Miyasaka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    N. Miyasaka
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021